Print

DEVELOPMENT PROGRAMS

The GuidAge study was set up to evaluate the effectiveness of EGb 761^® in preventing Alzheimer’s disease in patients aged over 70 spontaneously expressing memory complaints to their general practitioners. Recruitment of 2,800 patients was completed in November 2004 and those patients were treated over a five year period; the results of the study should be available in 2010.

Another study evaluating the effect of EGb 761^® on the cerebral metabolism of glucose (by neuroimaging) on three patient groups is also in progress: patients suffering from memory complaints both with and without objective cognitive disorders and patients with Alzheimer’s disease.

A further study evaluating the effects of EGb 761^® on mitochondrial metabolic functions in children with a rare genetic disorder, Friedreich’s ataxia, is also being carried out.